Viscum coloratum (Kom.) Nakai inhibits osteoclastogenesis in RANKL-induced osteoclast differentiation through the PI3K/AKT/mTOR pathway
Cytotechnology · 2026-04 · 78 (2)
DOI: 10.1007/s10616-026-00941-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytotechnology, online erschienen am 21.03.2026. Verfasst von Zhichao Hao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine), Ministry of Education, Harbin, 150040 Peopl…. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Heilongjiang Provincial Natural Science Foundation of China, Heilongjiang Province Double First Class Discipline Collaborative Innovation Achievement Construction Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Viscum coloratum (Kom.) Nakai has been widely used in traditional Chinese medicine and clinical treatment mainly for rheumatoid arthritis (RA). Our latest study demonstrated that it could alleviate clinical symptoms of RA and decrease osteoclastogenesis-related gene expression in the CIA mouse model. However, whether Viscum coloratum (Kom.) Nakai could inhibit osteoclastogenesis and its underlying mechanisms need to be further elucidated. In this study, we demonstrated that extract of Viscum coloratum (Kom.) Nakai (EVC) exhibited extraordinary activity against RANKL-induced osteoclast differentiation identified by inhibiting the formation of TRAP-positive multinucleated osteoclasts, TRAP activity, and decreasing osteoclast-specific genes NFATc1 expression. The network pharmacology-based method integrating Protein-Protein interaction analysis revealed that Viscum coloratum (Kom.) Nakai could inhibit osteoclastogenesis by regulating PI3K-AKT signaling pathways. Then, the predicted signaling pathway of EVC on osteoclast differentiation was determined by Western blot. Using TRAP activity and nitric oxide assays, Viscumneoside III, which was identified as the main ingredient from Viscum coloratum (Kom.) Nakai in our previous study, was confirmed as the primary effective ingredient. These findings reveal that EVC executed the traditional effects on strengthening muscles and bones for the treatment of RA by inhibiting osteoclastogenesis via the regulated PI3K/AKT/mTOR signaling pathway, and Viscumneoside III was its effective ingredient.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine), Ministry of Education, Harbin, 150040 People's Republic of China.
- College of Agriculture, Northeast Agricultural University, Harbin, 150030 China.
- College of Pharmacy, Heilongjiang University of Chinese Medicine, 24 Heping Road, Xiangfang District, Harbin, 150040 People's Republic of China.
Förderung
- Heilongjiang Provincial Natural Science Foundation of China
- Heilongjiang Province Double First Class Discipline Collaborative Innovation Achievement Construction Project
- National Natural Science Foundation of China
- Heilongjiang Chunyan Innovation Team Program
Zitieren
APA
Hao, Z., Liu, Y., Wang, Y., Yang, X., Pan, Y., Chen, Q., Zhang, L., Kuang, H., Li, Y., Wang, Y., Yang, B. Y., & Liu, Y. (2026). Viscum coloratum (Kom.) Nakai inhibits osteoclastogenesis in RANKL-induced osteoclast differentiation through the PI3K/AKT/mTOR pathway. Cytotechnology, 78(2). https://doi.org/10.1007/s10616-026-00941-9
Vancouver
Hao Z, Liu Y, Wang Y, Yang X, Pan Y, Chen Q, et al. Viscum coloratum (Kom.) Nakai inhibits osteoclastogenesis in RANKL-induced osteoclast differentiation through the PI3K/AKT/mTOR pathway. Cytotechnology. 2026;78(2). doi:10.1007/s10616-026-00941-9
BibTeX
@article{Hao2026,
author = {Hao, Zhichao and Liu, Yuan and Wang, Yanfu and Yang, Xu and Pan, Yan and Chen, Qingshan and Zhang, Lili and Kuang, Haixue and Li, Yuxin and Wang, Yiran and Yang, Bing-You and Liu, Yan},
title = {Viscum coloratum (Kom.) Nakai inhibits osteoclastogenesis in RANKL-induced osteoclast differentiation through the PI3K/AKT/mTOR pathway},
journal = {Cytotechnology},
year = {2026},
volume = {78},
number = {2},
doi = {10.1007/s10616-026-00941-9}
}
EUVIMED